Prescription status of edaravone and personal importation: Notice of update

Organizations and the provinces/territories continue to make progress in the marketing and reimbursement of edaravone (brand name Radicava). Currently, all provinces with the exception of Prince Edward Island (PEI) have updated their drug formularies to include edaravone for public reimbursement. The territories are still in the process of establishing full coverage.

Data and Resources

Additional Info

Field Value
Last Updated April 17, 2026, 22:05 (UTC)
Created April 17, 2026, 22:05 (UTC)
criticality_level []
geographic_scope []
open_canada_collection publication
open_canada_date_published 2021-09-28 00:00:00
open_canada_keywords {"fr": ["Approvisionnement en médicaments au Canada", "pénuries de médicaments", "GUI-0146", "exigences en matière de fourniture d'informations", "marché canadien des médicaments", "consommation de médicaments à l'extérieur du Canada", "accès aux médicaments", "intervenants dans la chaîne d'approvisionnement en médicaments", "stabilité de l'approvisionnement en médicaments"], "en": ["notice of update", "edaravone", "marketing of edaravone", "reimbursement of edaravone", "Radicava", "prescription status", "personal importation", "drug formularies"]}
open_canada_subject ["health_and_safety"]
sensitivity_level unrestricted
title_fr Statut de vente sur ordonnance et importation personnelle de l’édaravone : Avis de mise à jour
update_frequency as_needed